Burke-Hocoma Efficiency Study
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/16/2018 |
| Start Date: | May 1, 2016 |
| End Date: | December 2019 |
The ArmeoSpring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated
springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma
Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.
springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma
Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.
In the proposed study, 20 stable subacute and chronic stroke patients will be placed in two
groups: 2:1 treatment for 3 weeks (2 patients on 2 robots with one therapist; 60 minutes on
robot) then 1 on 1 intervention with the therapist (60 minutes of Hocoma Armeo Spring robotic
training) or visa versa. Patients will be assessed using robotic kinematics and standardized
occupational therapy motor assessments. The extreme precision afforded by robotic physical
rehabilitation therapies makes them an appealing and growing field in rehabilitation.
Determining efficiency of new technologies, while maintaining the highest quality of care, is
of priority in the medical field at this time. Devices such as the ArmeoSpring could lead to
reduced disability, thereby increasing function and improving quality of life in patients
experiencing neurological illness or injury. The ArmeoSpring has potential to decrease cost
for both the provider and patient over time while providing more engaging, evidence-based
therapy.
groups: 2:1 treatment for 3 weeks (2 patients on 2 robots with one therapist; 60 minutes on
robot) then 1 on 1 intervention with the therapist (60 minutes of Hocoma Armeo Spring robotic
training) or visa versa. Patients will be assessed using robotic kinematics and standardized
occupational therapy motor assessments. The extreme precision afforded by robotic physical
rehabilitation therapies makes them an appealing and growing field in rehabilitation.
Determining efficiency of new technologies, while maintaining the highest quality of care, is
of priority in the medical field at this time. Devices such as the ArmeoSpring could lead to
reduced disability, thereby increasing function and improving quality of life in patients
experiencing neurological illness or injury. The ArmeoSpring has potential to decrease cost
for both the provider and patient over time while providing more engaging, evidence-based
therapy.
Inclusion Criteria:
- Unilateral or bilateral upper extremity hemiparesis/hemiplegia
- Upper extremity Fugl-Meyer Assessment Score between 7-60 (Neither hemiplegic nor fully
recovered motor function of the shoulder, elbow, wrist)
Exclusion Criteria:
- Inability to follow 1-2 step commands
- Fixed joint contracture
- Unable to tolerate repetitious movement exhibited by pain greater than 5 on Likert
Scale
- Any device dependent restrictions
We found this trial at
1
site
Click here to add this to my saved trials
